Biotechnology

Greenblum and Bernstein’s biotechnology group covers the entire spectrum of biotechnology patent practice.

The group includes thirteen professionals (eleven attorneys and two agents) with extensive experience practicing in the biotechnology field. The average within the group is more than fifteen years of patent practice experience, and six members of the group are partners in the firm. The biotechnology group also has significant technical experience, with six members of the group having PhD degrees and post-doctoral research experience.

We have the experience and technical ability to advise our clients at all stages of their biotechnology business. We counsel start-up companies on invention disclosure documentation, laboratory notebook management, and patent filing strategies. We work with inventors to help them better understand how to capture their intellectual property, and draft, file, and prosecute applications on their behalf. We advise our clients on strategies for enforcement of their existing patents, and when the need arises, actively prosecute infringement and interferences before the USPTO and in the courts.

Client counseling is a critical area involving an understanding of not only the technology, but the marketplace, trends in the law and constantly evolving FDA guidelines as they relate to biosimilars, for example. We bring our experience to bear in counseling design-around strategies, as well as invalidity and non-infringement options.

For additional information concerning the Biotechnology Practice Group, please contact Sean C. Myers-Payne, Ph.D.,, Ph.D., or Walter A. Schlapkohl.